Dr. Reddy’s Laboratories announced Tuesday that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of the antiviral Valcyte (Valganciclovir) tablets, in the U.S. market.
The Generic Pharmaceutical Association on Wednesday expressed concerns that the current structure of the Trans-Pacific Partnership agreement (TPP) will impede generic utilization.
McKesson Patient Relationship Solutions on Wednesday announced the successful launch of LoyaltyScript@Retail.
The flu continues to pick up in pockets of the Midwest and across the South, according to the latest Walgreens Flu Index report, a weekly report developed to provide state- and market-specific information regarding flu activity.
Use of cigarettes, alcohol and abuse of prescription pain relievers among teens has declined since 2013, while marijuana use rates were stable, according to the 2014 Monitoring the Future survey, released Tuesday.
Greenstone announced the launch of celecoxib — the authorized generic version of Pfizer's Celebrex — to its line of generic pharmaceuticals.
Actavis on Tuesday announced the planned senior management team that will lead the global pharmaceutical company following the successful close of the acquisition of Allergan.
Novartis on Tuesday received approval from the Food and Drug Administration for Signifor long-acting release (pasireotide) for injectable suspension, for intramuscular use.
Dr. Reddy's Labs announced the launch of valganciclovir tablets USP in 450-mg strength.
Cardinal Health has introduced a new tool that gives pharmacists the ability to rapidly analyze antibiotic use trends.